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Thermostabilization of viruses via complex
coacervation†
Xue Mi, ‡a,b Whitney C. Blocher McTigue, ‡c Pratik U. Joshi,a,b
Mallory K. Bunker,a Caryn L. Heldt *a,b and Sarah L. Perry *c,d
Widespread vaccine coverage for viral diseases could save the lives of millions of people each year. For
viral vaccines to be eﬀective, they must be transported and stored in a narrow temperature range of
2–8 °C. If temperatures are not maintained, the vaccine may lose its potency and would no longer be
eﬀective in ﬁghting disease; this is called the cold storage problem. Finding a way to thermally stabilize a
virus and end the need to transport and store vaccines at refrigeration temperatures will increase access
to life-saving vaccines. We explore the use of polymer-rich complex coacervates to stabilize viruses. We
have developed a method of encapsulating virus particles in liquid complex coacervates that relies on the
electrostatic interaction of viruses with polypeptides. In particular, we tested the incorporation of two
model viruses; a non-enveloped porcine parvovirus (PPV) and an enveloped bovine viral diarrhea virus
(BVDV) into coacervates formed from poly(lysine) and poly(glutamate). We identiﬁed optimal conditions
(i.e., the relative amount of the two polypeptides) for virus encapsulation, and trends in this composition
matched diﬀerences in the isoelectric point of the two viruses. Furthermore, we were able to achieve a
∼103–104-fold concentration of virus into the coacervate phase, such that the level of virus remaining in
the bulk solution approached our limit of detection. Lastly, we demonstrated a signiﬁcant enhancement
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of the stability of non-enveloped PPV during an accelerated aging study at 60 °C over the course of a
week. Our results suggest the potential for using coacervation to aid in the puriﬁcation and formulation of
both enveloped and non-enveloped viruses, and that coacervate-based formulations could help limit the
need for cold storage throughout the transportation and storage of vaccines based on non-enveloped
viruses.

Introduction
According to the World Health Organization (WHO), millions
of people die from viral infectious diseases each year.1 One of
the most eﬀective methods to prevent viral infection is with
vaccines. In order for viral vaccines to be eﬀective, they must
be transported and stored in a “cold chain”.2 A cold chain is a
system of transporting and storing vaccines at the recommended temperature, typically 2–8 °C, from the manufacturer until the point of use.2,3 If temperatures are not main-
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tained, the vaccine may lose its potency and could no longer
be eﬀective in fighting disease.4 Approximately half of the vaccines produced each year are discarded due to poor thermal
stability.5 The unreliable cold chain system is one of the major
causes of inadequate immunization coverage in developing
countries.4 Therefore, developing robust, thermostable viral
vaccines that are less dependent on the cold chain is urgent
and crucial for universal access to immunizations.
There are three major types of viral-based vaccines licensed
for human use: live attenuated, inactivated, and subunit
vaccines.6,7 Live-attenuated vaccines are usually produced by
extended passage of a disease-causing (wild) virus in nonhuman cell culture to weaken the wild virus.8–10 The attenuated virus can still replicate and stimulate high immunity, but
has lost the ability to cause disease. Inactivated vaccines are
typically treated by chemical or heat inactivation to stop virus
replication.8–10 Thus, while inactivated viruses cannot replicate, they can still produce immunogenicity. Subunit vaccines
use a component of the virus, such as a surface polysaccharide, capsid protein, or nucleic acid, to stimulate an immune
response.8–10 Typically, live attenuated viruses raise the stron-
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gest immune response, followed by inactivated viruses, and
then subunit vaccines; however, the stability of these three
types of vaccines is in reverse order.6,7 Thus, live attenuated
viral vaccines tend to be the most sensitive to temperature
changes, and tight temperature control is required for them to
remain immunogenic.6 There is a need to develop versatile
methods to improve the thermal stability of live attenuated
vaccines.
Various methods have been developed to create thermostable viral vaccines, ranging from direct genetic
modification11,12 to changes in the formulation.13,14 However,
genetically modifying a viral vaccine is labour-intensive, virusspecific, and may not be accessible for some targets.11,12 A
more standard method to stabilize vaccine formulations is to
add stabilizing excipients.13,14 For example, high molar concentrations of sucrose were able to maintain the infectivity and
in vivo immunogenicity of an adenovirus serotype 5 at 37 °C
for 10 days.13
Further improvements in the thermal stability of virus formulations are often achieved via drying by lyophilization,
spray drying, or foam drying.15,16 Drying aims to slow down
the physical and chemical degradation of the vaccine.
However, these methods typically require the presence of
sugars (e.g., sucrose, mannitol, and trehalose), amino acids,
and/or other cryoprotectants and bulking agents that tend to
hydrogen bond with viral capsid proteins and/or viral envelopes to entrain surface-bound water and form a stabilizing
matrix.15–19 For example, lyophilized rotavirus vaccines formulated in optimized buﬀer conditions with polyvinyl pyrrolidone
as a bulking agent, sucrose as a cryoprotectant, and L-arginine
and glycine as osmolytes, can retain potency for 20 months at
37 °C and 7 months at 45 °C.18 An analogous strategy where
viral encapsulation in hydrated silica was used in place of an
organic matrix slowed the infectivity loss of the human enterovirus type 71 by six-fold at 37 °C for 20 days, or at 40 °C for
36 hours.20 Although such formulation methods show promise
for thermostabilizing vaccines, the outcomes tend to be the
result of large-scale trial and error experiments, and there is a
need for a simple, low-cost, and versatile approach for stabilizing viruses.
We propose the use of complex coacervation as a strategy
for improving the thermal stability of viral vaccines. Complex
coacervation is an associative liquid–liquid phase separation
phenomena that results from the electrostatic and entropic
interactions between oppositely charged macro-ions.21–24
Complex coacervation has a strong history of use as a method
of encapsulation in the food and personal care industries,25–30
and has gained recent attention for use in the fields of drug
delivery31–35 and gene therapy.36–38 A number of reports have
focused specifically on the incorporation of proteins into
complex coacervates, with a goal of protecting proteins against
degradation39,40 and potentially enhancing protein thermal
stability.41
We recently demonstrated the ability of two-polymer coacervates to eﬀectively encapsulate proteins with a range of
diﬀerent size and charge characteristics.42 Here, we adapt our
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Fig. 1 Schematic depiction of virus encapsulation via complex coacervation with two oppositely charged polypeptides.

approach, to study the encapsulation and potential for
thermal stabilization of two model viruses (Fig. 1). We characterized the complex coacervation of cationic poly(L-lysine)400
(K400) and negatively charged poly(D,L-glutamic acid)400 (E400)
in the presence of a non-enveloped porcine parvovirus (PPV)
and an enveloped bovine viral diarrhea virus (BVDV) as a function of the charge ratio of the two polymers present in solution, and quantified the uptake of virus into the coacervate
phase. Lastly, we performed accelerated aging studies to
characterize the thermal stability of our coacervate-virus formulations as a proof-of-concept for thermostabilizing vaccines
of live attenuated viruses.

Materials and methods
Materials
Potassium phosphate monobasic (molecular biology grade,
≥99.0%) and sodium chloride (NaCl, ACS grade, ≥99.0%) were
a gift from Millipore Sigma (Burlington, MA). Sodium phosphate dibasic heptahydrate (ACS grade, 98.0–102.0%), sodium
hydroxide (NaOH, ACS grade, ≥97.0%), sodium dodecyl sulfate
(SDS) and dimethyl sulfoxide (DMSO, BioReagent, >99.7%)
were purchased from Sigma-Aldrich (St Louis, MO).
Hydrochloric acid (HCl, ACS grade, 36.5–38.0%) and (4-(2hydroxyethyl)-1-piperazineethanesulfonic
acid)
(HEPES)
(≥99.0%) were purchased from Fisher Scientific (Pittsburgh,
PA). Pierce fluorescent dye 5-(and 6)-carboxy-tetramethyl-rhodamine succinimidyl ester (NHS-Rhodamine) was purchased
from Thermo Fisher Scientific (Waltham, MA). Thiazolyl blue
tetrazolium bromide (MTT) (98%) was purchased from Alfa
Aesar (Haverhill, MA). Minimum essential medium (MEM)
and Dulbecco’s modified Eagle’s medium (DMEM) were purchased from Life Technologies (Carlsbad, CA). Polypeptides
with a degree of polymerization of 400, poly(D,L-glutamic acid)
(E400) and poly(L-lysine) (K400), were purchased from Alamanda
Polymers (Huntsville, AL). The polypeptides were used as
received without further purification. Characterization information for the polypeptides is given in ESI Table S1.†
All aqueous solutions and buﬀers were prepared using purified water with a resistivity of ≥18 MΩ cm from a Nanopure filtration system (Thermo Scientific, Waltham, MA) and filtered
with a 0.2 µm bottle top filter (VWR, Radnor, PA) or a 0.2 µm
syringe filter (VWR) prior to use. Phosphate buﬀered saline
(PBS) ( pH 7.20 ± 0.03) was prepared by dissolving 0.21 g pot-
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assium phosphate monobasic, 0.73 g sodium phosphate
dibasic heptahydrate, and 9.0 g NaCl into 1000 mL Nanopure
water. Stock solutions of 10 mM polypeptide solutions were
prepared on a charged monomer basis and adjusted with 1 M
HCl and 1 M NaOH to the desired pH 8.00 ± 0.03 pH units.
Zwitterionic buﬀer solution of 0.4 M HEPES was also adjusted
with 1 M HCl and 1 M NaOH to the desired pH 8.00 ± 0.03 pH
units.
Virus production, purification, and titration
Porcine kidney cells (PK-13, CRL-6489) and bovine turbinate
cells (BT-1, CRL-1390) were purchased from ATCC. Porcine parvovirus (PPV) strain NADL-2, was a gift from Dr. Ruben
Carbonell (North Carolina State University, Raleigh, NC). Bovine
viral diarrhea virus (BVDV) strain NADL was purchased from
USDA APHIS. PPV was propagated in PK-13 cells, and BVDV was
propagated in BT-1 cells, as described previously,43,44 and
stored at −80 °C until further use. PPV or BVDV were further
purified with a Biotech Cellulose Ester 1000 kDa dialysis tubing
(Rancho Dominguez, CA) and a BioRad Econo-Pac 10DG desalting column (Hercules, CA) in PBS buﬀer, as previously
described,45 and stored at 4 °C until further use.
To determine the concentration of the infectious virus, an
MTT assay was used. Briefly, either 8 × 104 cells per mL PK-13
cells in completed MEM media (to titrate PPV)46 or 2.5 × 105
cells per mL BT-1 cells in completed DMEM media (to titrate
BVDV)47 were seeded in a clear, flat-bottom, 96-well plate in a
volume of 100 µL per well. After one day of incubation, 25 µL
per well of virus sample was added to the corresponding host
cells in quadruplicate and serially diluted across the plate.
After 6 days post-inoculation, 10 μL per well of 5 mg mL−1
MTT reagent in PBS ( pH 7.2) was added to the plate. After
4 hours, 100 μL per well of solubilizing agent, 10% SDS in 0.01
M HCl ( pH 2.5), was added to the plate. After 12 to 24 hours,
plates were read at 550 nm in a Synergy Mx monochromatorbased multimode microplate reader (Winooski, VT). The virus
dilution that killed 50% of the cells is stated as the virus titer
MTT50.44 A similar procedure was used to quantify the cytotoxicity of the coacervates and the individual peptides (see
ESI† for details).
Formation of virus-containing complex coacervates
Virus-containing complex coacervate samples were formed by
first pipetting water, and then HEPES buﬀer into a 1.7 mL
microcentrifuge tube, followed by the virus (PPV or BVDV),
K400, and E400. The samples were vortexed for 5 seconds after
the addition of each polypeptide to ensure fast and complete
mixing. The recipes for each sample of PPV- and BVDV-containing complex coacervates are detailed in ESI Tables S2 and
S3,† respectively. A typical experiment contained a total
volume of 240 µL and maintained a constant total polymer
concentration of 7 mM (on a monomer basis) while varying
the ratio of K400 to E400. The concentration of virus was also
maintained constant at 4, 5, and 6 log (MTT50 per mL) for PPV
and 4 and 5 log (MTT50 per mL) for BVDV, and all experiments
were performed in 10 mM HEPES buﬀer, pH 8.0. All virus-con-
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taining complex coacervates were prepared immediately before
use and studied at room temperature. All experiments were
performed in triplicate.
Virus complex coacervates characterization and quantification
We used turbidity to qualitatively measure the formation of
the virus-containing complex coacervates. Briefly, turbidity was
measured by placing 100 µL of the sample into a clear, flatbottom, 96-well plate and measuring the absorbance at
562 nm using a Synergy Mx monochromator-based multimode
microplate reader (Winooski, VT).42,48 The measured signal
was referenced against a control well containing only
Nanopure water and HEPES buﬀer. Samples were then examined using an Olympus IX51 microscope with a DP72 camera
(Center Valley, PA) to confirm the presence or absence of coacervation, and the 100 µL aliquot was recovered for subsequent
use in the infectivity assay. Only two concentrations of BVDV
coacervates were studied due to the initial concentration of
enveloped BVDV propagated being lower than PPV.
Viruses were also labelled with a fluorescent dye
NHS-Rhodamine that absorbs visible green light at a wavelength of 552 nm and emits orange-red visible light at 575 nm
to confirm the presence of the virus in the coacervate phase.
1 mL of purified virus solutions (8 log PPV or 7 log BVDV) were
incubated with 10 mg mL−1 NHS-Rhodamine in DMSO solution (2.15 μL for PPV and 6.5 μL for BVDV) for 1 hour at room
temperature. Excessive non-tagged fluorescent dye was
removed with a BioRad Econo-Pac 10DG desalting column.
The fluorescently labelled virus was used immediately to form
the virus coacervate, as described above. An aliquot of 100 μL
of tagged virus coacervates was transferred to one well of a
96-well plate and examined with an Olympus IX51 microscope.
The coacervates droplets were imaged using both brightfield
and fluorescence modes and analysed with ImageJ.
An MTT virus infectivity assay was used to quantify the
amount of virus present in both the coacervate and the supernatant phases.44 The 240 μL sample containing the complex
coacervate and virus in the microcentrifuge tube was centrifuged using an ST16R Centrifuge (Thermo Scientific, Asheville,
NC) at 14 000 rpm (21 475g) for 20 min at 15 °C to separate the
supernatant from the dense coacervate phase. Following centrifugation, the supernatant volume was carefully measured
and transferred into a new microcentrifuge tube via pipetting.
A volume of 220 µL of 2 M NaCl solution was added to the
dense coacervate phase (transparent gel) to dismantle the coalesced virus coacervate, followed by vortexing. The concentration of virus in both the supernatant and dismantled coacervate was then titrated by the MTT assay. The volume of the
coacervate phase was neglected, though we estimated that the
maximum volume of coacervate formed was approximately
∼1 µL. These values were then used to calculate the partitioning of the virus into the complex coacervate phase. The partition coeﬃcient (K) was calculated as:
K¼

Cc
Cs

ð1Þ
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where Cc is the virus concentration in the coacervate phase,
and Cs is the virus concentration in the supernatant phase.
Virus thermal stability study
Thermal stability studies were performed using samples
where maximal virus partitioning was observed, (i.e., a charge
fraction of 0.5 for PPV and 0.6 for BVDV). A microcentrifuge
tube containing either the PPV dense coacervate phase or
purified PPV was capped and wrapped in Parafilm and put in
a digital dry bath (USA Scientific, Ocala, FL) at 60 °C. The
BVDV complex coacervate and purified BVDV were similarly
put in the dry bath at 40 °C. At each time point, a tube containing ∼1 µL of the dense, virus-containing coacervate
sample was removed from the heating block and dismantled
in 220 µL of 2 M NaCl. A purified virus sample was also
removed from the heat at the same time. The experiment was
performed in triplicate. Both samples were then titrated with
the MTT assay to determine the remaining infectious virus
concentrations. A log reduction value (LRV) of the virus was
calculated as:
 
Cf
LRV ¼ log10
ð2Þ
Ci
where Cf is the final virus concentration after heat treatment,
and the Ci is the initial virus concentration.
The lifetime of infectious PPV particles τ was determined
using a simple model for infectivity loss:13
nðtÞ ¼ n0 e t=τ

ð3Þ

where t is the length of thermal treatment, n(t ) is virus titer at
t, n0 is the initial virus titer, and τ is the inverse decay rate
corresponding to the mean lifetime of an infectious viral
particle.
Statistical analysis
Statistical analysis was performed using an unpaired, twotailed Student’s t test. An asterisk (*) denotes p < 0.05 between
samples.

Results and discussion
The goal of this work was to determine if complex coacervation
could be used to encapsulate and thermally stabilize viruses.
To this end, we studied the encapsulation and stabilization of
two model viruses, non-enveloped PPV and enveloped BVDV.
This approach allowed us to explore potential diﬀerences
between enveloped and non-enveloped viruses.

Table 1

Encapsulation of virus
Previous reports on protein encapsulation using coacervates
emphasized the importance of electrostatic interactions in
driving protein incorporation.42,52–57 Therefore, it is important
to consider the charge state of the viruses used in our study.
Table 1 outlines some of the physical properties of the chosen
viruses. Notably, both viruses have an acidic isoelectric
point,43 meaning that the particles will carry a net negative
charge at most physiologically-relevant solution conditions,
and will become more negatively charged at higher pH
conditions.
However, in the context of complex coacervation, we must
balance the charge state of our viruses with that of the two
complexing polypeptides.42 Therefore, because both PPV58 and
BVDV are stable at pH 8.0,59 we elected to perform our experiments at a solution pH of 8.0 using 10 mM HEPES as a
neutral, zwitterionic buﬀer. This solution condition maximizes
the negative charge of the virus particles while limiting
the loss of charge from the poly(lysine). Furthermore, our
previous eﬀorts with proteins had indicated that protein
encapsulation decreased dramatically at higher ionic strength
conditions.42,53,54 Therefore, experiments were performed in
the absence of added salt.
In order to identify optimal conditions for viral encapsulation, we performed coacervation experiments at levels of constant virus concentration and constant total polypeptide concentration while varying the relative amounts of the polycation
K400 and polyanion E400. Fig. 2 shows the characteristic optical
micrographs of the resulting samples, prepared with the fluorescently labelled virus. Colocalization of the fluorescent signal
with the droplets confirmed the successful incorporation of
both PPV and BVDV into our complex coacervates. It should be
noted that our study did not aim to create a coacervate formulation with a specified droplet size, and the coacervate droplets
in our samples coalesce over time. Careful consideration of
these types of physical properties would be necessary for translation of this method into actual practice, but are beyond the
scope of the current work.
Turbidity measurements, along with visual inspection via
optical microscopy, were used to identify the presence or
absence of phase separation (Fig. 3). We observed a general
increase in the turbidity signal with increasing virus concentration, consistent with an increase in the total volume of coacervate present, although the qualitative nature of turbidity is
such that we cannot decouple an increase in the number of
coacervate droplets from changes in droplet size.
The maximum turbidity signal for all samples was observed
at a cationic polymer charge fraction below 0.50, corres-

Model virus properties, including size, isoelectric point ( pI), and related human viruses

Virus

Capsid

Family

Nucleic acid

Size (nm)

pI

Related human viruses

Ref.

Porcine parvovirus (PPV)
Bovine viral diarrhea virus (BVDV)

Non-enveloped
Enveloped

Parvoviridae
Flaviviridae

ssDNA
ssRNA

18–26
40–60

4.8–5.1
4.3–4.5

B-19 human parvovirus
Hepatitis C

43, 49 and 50
43, 49 and 51
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Fig. 2 (a and d) Brightﬁeld, (b and e) ﬂuorescence, and (c and f ) merged optical micrographs of (a–c) PPV- and (d–f ) BVDV-containing coacervate
droplets, demonstrating virus encapsulation.

Fig. 3 Turbidity of the encapsulated virus as a function of the polymer
charge fraction associated with cationic K400 for coacervates prepared
with diﬀerent concentrations of (a) PPV and (b) BVDV. All data points are
the average of three separate tests, and error bars represent the standard deviation.

ponding to “net negative” conditions. This result is somewhat
unexpected, as the acidic pI of both viruses would suggest that
optimal coacervation would be expected at a “net positive”

This journal is © The Royal Society of Chemistry 2020

polymer ratio.42,55,57 However, the turbidity signal for all but
one of our samples also showed a bimodal shape, with the
second peak located at higher charge fractions. This bimodal
signal likely indicates a heterogeneous population of viruses,
where each turbidity peak represents a distinct virus population, which is common,60 and could explain the unexpected
results.
While optical microscopy and turbidity confirmed the successful formation of virus-containing coacervates, it did not
provide quantitative information on the amount of virus
sequestered in the coacervates. Therefore, we employed an
MTT cell viability assay to quantify the concentration of infectious virus in both the supernatant and coacervate phases. The
plots of virus titer as a function of coacervate charge stoichiometry in Fig. 4 showed strong extraction of both PPV and
BVDV into the coacervate phase that was matched by a commensurate decrease in the virus titer for the supernatant
phase.
Interestingly, we only observed a single peak in our virus
titer data, corresponding to the second peak in the turbidity
measurements (i.e., the peak at higher, “net positive” charge
fractions). For PPV, this maximum sequestration was observed
near a charge ratio 0.5 (Fig. 4a–c), while for BVDV, the
maximum occurred near a charge ratio of 0.6 (Fig. 4d and e).
This diﬀerence in the peak location is likely explained by the
fact that pI of BVDV is more acidic than PPV (Table 1),
suggesting the potential for a higher net charge at our experimental conditions of pH = 8.0.
Fig. 5 plots the logarithmic value of the partition coeﬃcient
ln(K), where a positive value indicates that the viral particles
favoured the coacervate phase, while a negative value indicates
that the viral particles remained in the supernatant phase.
While the trends in partition coeﬃcient derive from those
already described in terms of viral titer, what is particularly
noteworthy is the magnitude of the partition coeﬃcient. We
observed a trend of increasing maximum partition coeﬃcient
with the initial viral concentration that achieved 6.2 × 104 fold
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Fig. 4 Live virus titration as a function of the polymer charge fraction associated with cationic K400 for both the supernatant (open symbols) and
coacervate (closed symbols) phases for samples prepared with diﬀerent total starting concentrations of (a–c) PPV and (d and e) BVDV. All data
points are the average of three separate tests, and error bars represent the standard deviation.

Fig. 5 Partition coeﬃcient as a function of the polymer charge fraction associated with cationic K400 for coacervates prepared with diﬀerent concentrations of (a–c) PPV and (d and e) BVDV. All data points are the average of three separate tests, and error bars represent the standard deviation.

increase for PPV and 2.4 × 103 fold increase for BVDV. This
ability to both sequester and concentrate virus has tremendous
potential for applications related to virus purification and formulation. For example, an aqueous two-phase system of poly
(ethylene glycol) and salt was only able to achieve an approximate 10-fold partitioning of bacteriophage M13.61

Biomater. Sci.

These observed trends in virus titer and partitioning are
also matched by a calculation of the virus recovery into the
coacervate phase (ESI Fig. S1†). While our results indicate
100% recovery of PPV into the coacervate phase, we were only
able to recover approximately 50% of BVDV. This is likely due
to the lower stability of the enveloped BVDV in the high ionic

This journal is © The Royal Society of Chemistry 2020
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strength conditions used to dissolve the coacervate, as high
concentrations of salt can cause leakage in the viral envelope
membrane.62 Alternative strategies for destabilizing the coacervate could potentially circumvent this challenge, but are
beyond the scope of the current work.
Thermal stability of encapsulated vs. free virus
To demonstrate the eﬀect of complex coacervates on the stability of viruses against high temperatures, we sought to identify
accelerated aging conditions for a stability study, using conditions where the viruses would become completely inactivated over a reasonable experimental lifetime. Literature
reports on the stability of purified solutions of virus suggested
the use of 60 °C for PPV, as a 1 log loss of infectivity was
observed for this non-enveloped virus after 1 hour.63 For
BVDV, we selected temperature of 40 °C, having observed a
50% loss of infectivity at 37 °C for 6 hours.64
We performed stability studies, comparing solutions of free
virus in aqueous solution with an equivalent amount of total
virus encapsulated in our optimum coacervate conditions. At
each time point, a sample of both free and encapsulated virus
was removed from heat, the coacervate phase was disassembled by the addition of 2 M NaCl to the coacervate
sample, and the viral titer was determined (ESI Fig. S2†). From
these data, we calculated the loss of activity over time as a log
reduction value (LRV).
For PPV, we observed significant retention of activity due to
encapsulation (Fig. 6a). After 1 day at 60 °C, encapsulated PPV
eﬀectively maintained its viral titer, only losing 1.0 log ± 0.1
log (MTT50 per mL). In comparison, free PPV showed a LRV of
2.9 log ± 0.3 log (MTT50 per mL) after 1 day. Moreover, free
PPV in solution was found to be completely inactivated after 7
days under 60 °C, with an LRV of 5.9 ± 0.5 log (MTT50 per mL),
while encapsulated PPV only suﬀered a titer loss of 2.7 log ±
0.1 log (MTT50 per mL) after 7 days.
We can further use a simple lifetime model to calculate
infectivity loss (eqn (3)). This model assumes the infectious
viral particles degraded from infectious to a disrupted state at
a constant rate and was fit to the titer data (ESI Fig. S2a†).
Based on this model, we determined a lifetime for our encapsulated PPV to be 14 days at 60 °C, which is significantly
longer than the 4-day lifetime of free PPV at 60 °C. Using the
Simonelli and Dresback’s Q10 factor for shelf-life determination and a Q10 value of 2, 7 days at 60 °C is equivalent to
3 months at 22 °C. While a 2 LRV loss would be too much for
an FDA approved vaccine, this method shows promise as a
method to thermally stabilize non-enveloped viruses at room
temperature.65,66
We hypothesize that the enhanced thermal stability of
encapsulated PPV compared to the free PPV could be attributed to crowding eﬀects associated with the high concentrations
of polymer and virus present in the coacervate. These types of
excluded volume eﬀects typically disfavour protein unfolding
and denaturation events that could be associated with loss of
viral activity.40,67 The main driving force for viral capsid
protein unfolding is believed to be the high conformational
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Fig. 6 Thermal stability deﬁned as the log reduction value (LRV) as a
function of time for free and encapsulated (a) PPV and (b) BVDV. All data
points are the average of three separate tests, and error bars represent
the standard deviation. Lines are a guide for the eye. An asterisk (*)
denotes p < 0.05 comparing encapsulated and free samples at the same
time point.

entropy of the denatured state,68 as the flexible unfolded state
has more conformational degrees of freedom than the
compact folded state. The limited volume of the crowded coacervate environment would therefore minimize the number of
accessible conformational degrees of freedom for the unfolded
state, and hence stabilize the native state of the viral
protein.68–70 While there is also the potential for enthalpic
contributions to protein stability,41,71,72 exploration of these
eﬀects would require modulation of the coacervate materials,
and is beyond the scope of the current work.
Given the promising improvements in stability seen for PPV
(a non-enveloped virus), we similarly explored the stability of
BVDV as a model enveloped virus (Fig. 6b and S2b†). However,
complex coacervates oﬀered no protection for BVDV against
high temperatures. In fact, the data showed that encapsulated
samples inactivated faster than free BVDV. We hypothesize
that the lipid envelope surrounding the capsid provides a
similar entropic stabilization eﬀect for BVDV, as was described
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in the context of the coacervate for PPV. However, interactions
between the coacervate and the lipid bilayer could adversely
aﬀect the stability of both the membrane and the virus. Poly
(lysine) is known to penetrate negatively charged lipid
bilayers,73 and can have cytotoxic eﬀects at high concentrations. However, while a dose-dependent poly(lysine) cytotoxicity was observed for both the PK-13 and BT-1 cells used in
this study, it is interesting that the coacervate showed no toxicity with the BT-1 cells used alongside BVDV, while some toxicity was observed for PK-13 cells (ESI Fig. S3†). However, viral
envelopes do not play precisely the same role as the membranes of more complex organisms, and potential interference
with the BVDV envelope could explain the nearly 2 log diﬀerence in initial activity observed for BVDV, as well as the 50%
recovery levels of BVDV in coacervates (ESI Fig. S1†). It is possible that these adverse eﬀects could be overcome by a change
in coacervate materials and/or experimental methodology.
However, such investigations are beyond the scope of the
current work.

Conclusions
In summary, we explored the encapsulation of two model
viruses, a non-enveloped PPV and an enveloped BVDV, into
polypeptide-based complex coacervates. This first proof-ofconcept demonstration of viral encapsulation highlighted the
tremendous potential for using complex coacervation as a
strategy for extracting virus from aqueous solution with near
100% recovery for non-enveloped viruses. Furthermore, strong
partitioning of the viruses into the coacervate phase allowed
for an increase in virus concentration on the order of 6.2 × 104/
2.4 × 103 fold for PPV/BVDV. While these two aspects of downstream viral processing each have significant potential to
impact strategies for the purification, concentration, and formulation of viruses, we also demonstrated a significant
enhancement in the thermal stability of the non-enveloped
PPV. Although more detailed studies on the intermolecular
interactions driving these eﬀects is needed, across a range of
additional viruses, our results suggest that complex coacervation could help to improve the thermal stability of at least nonenveloped viral vaccines, thereby decreasing the need for a
cold chain to maintain their eﬃcacy, decreasing costs, and
improving accessibility.
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